Shots:

• The NOC is based on the positive data of Calquence in ACE-LY-004 trial demonstrating 81% OR rate for patients with relapsed or refractory MCL
• The Health Canada approval of Calquence allows AstraZeneca to develop the treatments of blood cancers
• Calquence (acalabrutinib- previously known as ACP-196) is an oral selective inhibitor of Bruton's tyrosine kinase (BTK) which further irreversibly binds to it while inhibiting its activity- with its recommended dose one 100mg capsule administered twice daily

Click here to­ read full press release/ article 

Ref: Newswire | Image: AstraZeneca